EyePoint (EYPT) vs 10x Genomics (TXG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
10x Genomics (TXG) has outperformed EyePoint (EYPT) over the past year, gaining 540.3% versus a loss of 75.1%. Over five years, TXG leads with a -49.2% price change compared with -69.8% for EYPT. 10x Genomics is the larger company by market cap ($11.00 billion vs $295.0 million), about 37.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EYPT | TXG |
|---|---|---|
| Share price | $3.52 | $84.41 |
| Market cap | $295.00M | $11.00B |
| 1-day change | +1.69% | +9.22% |
| YTD return | -81.06% | +373.82% |
| 1-year return | -75.07% | +540.27% |
| 5-year return | -69.76% | -49.25% |
| EPS (TTM) | $-3.75 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $642.82M |
| Revenue growth (YoY) | — | +5.25% |
| Net income (latest FY) | — | $-43.54M |
| Gross margin | — | 69.05% |
| Operating margin | — | -9.49% |
| Net margin | — | -6.77% |
| 52-week high | $19.11 | $102.81 |
| 52-week low | $3.05 | $11.16 |
| Distance from 52-week high | -81.59% | -17.90% |
| Analyst consensus | none | buy |
| Avg. price target upside | +636.37% | -20.06% |
| Average volume | 3.96M | 3.29M |
| Shares outstanding | 83.84M | 120.21M |
| Employees | 214 | 1,178 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- 10x Genomics is about 37.3 times larger than EyePoint by market value ($11.00B vs $295.00M).
- TXG has outperformed EYPT by 615.3 percentage points over the past year.
About EyePoint
EYPT stock →EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.
Industrials · Biotechnology: Laboratory Analytical Instruments · 214 employees
About 10x Genomics
TXG stock →10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific.
Industrials · Biotechnology: Laboratory Analytical Instruments · 1,178 employees
EYPT vs TXG FAQ
Which is bigger, EyePoint or 10x Genomics?
10x Genomics (TXG) is larger, with a market capitalization of $11.00B compared with $295.00M for EyePoint (EYPT).
Which stock has performed better over the past year, EYPT or TXG?
TXG returned +540.27% over the past 12 months, compared with -75.07% for EYPT (price return, excluding dividends). Past performance does not predict future results.
Are EyePoint and 10x Genomics in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.